JPMorgan Chase & Co. reissued their overweight rating on shares of G1 Therapeutics (NASDAQ:GTHX) in a research note published on Tuesday. They currently have a $39.00 price objective on the stock, up from their prior price objective of $33.00.
GTHX has been the subject of a number of other reports. BidaskClub upgraded shares of G1 Therapeutics from a sell rating to a hold rating in a research note on Wednesday, January 3rd. Cowen reiterated a buy rating on shares of G1 Therapeutics in a research note on Monday, March 5th. BTIG Research reiterated a buy rating and issued a $38.00 price objective on shares of G1 Therapeutics in a research note on Thursday, February 22nd. Finally, Zacks Investment Research upgraded shares of G1 Therapeutics from a sell rating to a hold rating in a research note on Monday, February 26th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The company presently has an average rating of Buy and a consensus target price of $36.60.
G1 Therapeutics (NASDAQ GTHX) opened at $34.23 on Tuesday. G1 Therapeutics has a one year low of $12.04 and a one year high of $35.24.
In other news, insider Rajesh Malik sold 3,776 shares of the business’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $20.00, for a total transaction of $75,520.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mark A. Velleca sold 7,500 shares of the business’s stock in a transaction on Monday, December 18th. The shares were sold at an average price of $20.01, for a total transaction of $150,075.00. The disclosure for this sale can be found here. Insiders have sold a total of 217,302 shares of company stock valued at $4,314,417 over the last 90 days.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. American International Group Inc. purchased a new position in shares of G1 Therapeutics during the 3rd quarter valued at $130,000. California State Teachers Retirement System purchased a new position in shares of G1 Therapeutics during the 3rd quarter valued at $319,000. Teachers Advisors LLC grew its position in shares of G1 Therapeutics by 44.6% during the 4th quarter. Teachers Advisors LLC now owns 13,818 shares of the company’s stock valued at $274,000 after purchasing an additional 4,260 shares in the last quarter. Swiss National Bank purchased a new position in shares of G1 Therapeutics during the 4th quarter valued at $286,000. Finally, Schwab Charles Investment Management Inc. purchased a new position in shares of G1 Therapeutics during the 3rd quarter valued at $364,000. Hedge funds and other institutional investors own 47.54% of the company’s stock.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.